Short Summary
The PTAB denied institution of the IPR, finding that the Petitioner failed to demonstrate a reasonable likelihood of prevailing on its grounds of obviousness (103). The challenge targeted multiple claims related to Tire Pressure Monitoring Systems using various prior art combinations.
Detailed Summary
CUB Elecparts Inc.'s petition challenging 12 claims of Orange Electronic Co., Ltd.'s patent was denied by the PTAB, which found that the Petitioner failed to meet the burden of showing a reasonable likelihood of prevailing on its grounds of obviousness (35 U.S.C. § 103). The challenge relied heavily on combinations involving Tang and Lemense, among others. Specifically, the Board noted deficiencies in the Petitioner's reasoning regarding key limitations, such as the requirement that 'the old tire pressure detector stores only the old identification,' leading to the denial of institution despite the petitioner's arguments.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in CUB Elecparts Inc. vs Orange Electronic Co., Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Azurity Pharmaceuticals, Inc. et al.vsHeron Therapeutics, Inc.
Azurity has filed a PGR petition seeking cancellation of claims 1‑30 of Heron’s U.S. 12,115,254 patent covering injectable aprepitant emulsions. The petition alleges obviousness over four prior‑art references and asserts lack of written description and enablement due to overly broad claim ranges. Institution is requested and discretionary denial is contested.
NVIDIA CorporationvsOnesta IP, LLC
NVIDIA has filed an IPR petition challenging the validity of Onesta IP's U.S. Patent 11,841,803.
ClearCorrect Operating, LLC et al.vsAlign Technology, Inc.
The USPTO Director denied ClearCorrect's request to review the institution decisions in several IPRs involving Align Technology's orthodontic patents, leaving the institution rulings in place.
Intas Pharmaceuticals, Ltd. et al.vsAtossa Therapeutics, Inc.
Intas Pharmaceuticals challenges Atossa Therapeutics’ endoxifen patent in IPR 2025‑00799. The petitioner argues the Board correctly instituted the case and that the Patent Owner’s new arguments are unsupported. The response seeks denial of the Owner’s request for Director Review.
Meta Platforms, Inc.vsMullen Industries LLC
Meta Platforms has filed an IPR petition seeking to invalidate three claims of Mullen Industries’ location‑based gaming patent, arguing they are obvious over the earlier Levine application. The petition cites dismissal of the patent in a related district‑court case and argues no discretionary denial factors apply.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.